Zoledronic Acid (Reclast) in Black / African Ancestry Patients: Documented Efficacy Gaps

Why the Evidence Base Is Thin for Black Patients

Black and African ancestry patients are underrepresented in every major bisphosphonate trial. The data gap is not unique to zoledronic acid, but its consequences are clinically significant because physicians cannot quote race-specific fracture reduction numbers with confidence.

The HORIZON-PFT Enrollment Problem

The HORIZON Key Fracture Trial (HORIZON-PFT) randomized 7,765 postmenopausal women with osteoporosis to zoledronic acid 5 mg IV yearly or placebo over three years 1. The trial reported a 70% reduction in morphometric vertebral fractures (3.3% vs. 10.9%, RR 0.30, 95% CI 0.24-0.38) and a 41% reduction in hip fractures (1.4% vs. 2.5%, HR 0.59, 95% CI 0.42-0.83). These are strong numbers. They are also derived almost entirely from White and Asian participants.

Fewer than 2% of HORIZON-PFT participants were Black 1. The HORIZON Recurrent Fracture Trial, which studied zoledronic acid after hip fracture repair, had a similarly narrow racial composition 2. No published subgroup analysis from either trial reports fracture outcomes stratified by Black race with adequate statistical power.

A Pattern Across Bisphosphonate Research

This is not an isolated oversight. A 2021 systematic review of osteoporosis RCTs found that Black participants represented only 0.5-3% of enrolled subjects across all major bisphosphonate and denosumab trials 3. The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis acknowledged this gap, stating: "Evidence for fracture risk reduction with pharmacotherapy is derived predominantly from studies of White postmenopausal women, and applicability to other populations remains uncertain" 4.

Bone Density, Fracture Risk, and the Racial Paradox

Black patients present a clinical paradox that complicates direct extrapolation of trial data. Understanding this paradox is necessary before interpreting zoledronic acid efficacy.

Higher BMD Does Not Mean Zero Risk

On average, Black American women have 5-10% higher areal bone mineral density (aBMD) at the hip and spine compared to White women of the same age 5. This difference partly explains lower overall hip fracture incidence. But "lower" does not mean "absent." Data from the Women's Health Initiative (WHI) showed that Black women still experience 218 hip fractures per 100,000 person-years in the 70-79 age group, roughly half the rate in White women but far from negligible 6.

The assumption that Black patients do not get osteoporosis has contributed to dramatic underscreening. A 2020 analysis of Medicare claims found that Black women aged 65-74 were 50% less likely to receive a DXA scan than White women in the same age range 7. When fractures do occur, they carry the same morbidity. One-year mortality after hip fracture in Black patients is comparable to or higher than in White patients 8.

FRAX and Its Calibration Limits

The U.S. FRAX tool includes a "Black" ethnicity option that adjusts 10-year fracture probability downward based on population-level epidemiologic data from Malmö (Sweden) recalibrated to U.S. Hip fracture rates. The National Osteoporosis Foundation (now Bone Health & Osteoporosis Foundation) recommends using the ethnicity-specific FRAX input when available 9. The calibration, however, relies on fracture incidence data that may undercount fractures in Black populations due to the same screening disparities described above.

A practical approach: treat FRAX as a minimum estimate in Black patients, not a ceiling. If clinical suspicion is high (glucocorticoid use, prior fragility fracture, family history), consider treatment even when the FRAX score falls below the standard 20%/3% thresholds.

Vitamin D Status and Bisphosphonate Response

Vitamin D insufficiency directly affects how well zoledronic acid works. This factor is disproportionately relevant in Black patients.

Prevalence of Vitamin D Insufficiency

NHANES data show that 61% of Black American adults have serum 25(OH)D levels below 20 ng/mL (50 nmol/L), compared to 14% of White Americans 10. Among Black women over 65, the prevalence of vitamin D insufficiency exceeds 75% in some cohorts. This is driven by higher melanin content reducing cutaneous vitamin D3 synthesis, lower dietary intake, and less supplement use.

Why This Matters for Zoledronic Acid Specifically

Bisphosphonates, including zoledronic acid, inhibit osteoclast-mediated bone resorption. Their efficacy depends on adequate calcium and vitamin D to support the coupled bone formation response. The HORIZON-PFT protocol required all participants to receive calcium 1,000-1,500 mg/day and vitamin D 400-1,200 IU/day 1. Patients with 25(OH)D levels below 15 ng/mL were excluded or repleted before randomization.

In real-world practice, this pretreatment repletion step is sometimes skipped. A 2018 retrospective cohort study found that 34% of patients receiving their first zoledronic acid infusion had no documented vitamin D level in the preceding 12 months 11. When patients are infused while vitamin D-deficient, symptomatic hypocalcemia can occur, and the BMD gains may be blunted.

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research & Osteoporosis Center, has noted: "Correcting vitamin D deficiency before bisphosphonate therapy is not optional. It is a prerequisite for both safety and efficacy, and this step is missed more often in populations already burdened by health care disparities" 4.

Pharmacogenomic Considerations

Zoledronic acid is a nitrogen-containing bisphosphonate that inhibits farnesyl diphosphate synthase (FDPS) in the mevalonate pathway. It is not metabolized by cytochrome P450 enzymes and is excreted unchanged by the kidneys. This pharmacokinetic profile limits the number of pharmacogenomic variables that could alter drug exposure.

FDPS and GGPS1 Variants

Single-nucleotide polymorphisms in FDPS (rs2297480) and geranylgeranyl diphosphate synthase (GGPS1, rs3840452) have been associated with variable BMD response to oral bisphosphonates in some candidate-gene studies 12. The rs2297480 minor allele frequency differs by ancestry: approximately 45% in European populations and 25% in West African populations, according to gnomAD data.

Clinical Significance Remains Unclear

No prospective trial has stratified zoledronic acid outcomes by FDPS or GGPS1 genotype. A 2016 PharmGKB review rated the evidence for bisphosphonate pharmacogenomics as level 3 (low), noting that "replication in diverse ancestral populations is lacking, and no actionable clinical recommendations can be made" 13. The CYP2C8 enzyme, sometimes mentioned in the context of bisphosphonate research, does not play a role in zoledronic acid clearance because the drug bypasses hepatic metabolism entirely.

For now, ancestry-based dose adjustments for zoledronic acid have no pharmacogenomic justification. The standard dose is 5 mg IV once annually for osteoporosis treatment and 5 mg IV once every two years for osteoporosis prevention, regardless of race 14.

Renal Function and Dosing in Black Patients

Renal safety is the primary dosing constraint for zoledronic acid. The FDA label contraindicates the drug when creatinine clearance is below 35 mL/min 14. Race intersects with renal dosing through two pathways.

eGFR Equation Updates

The 2021 CKD-EPI equation removed the race coefficient that previously adjusted eGFR upward for Black patients 15. The older equation (CKD-EPI 2009) added approximately 16% to eGFR for Black patients, which could mask CKD and make a patient appear eligible for zoledronic acid when their true filtration rate was below the safety threshold.

Clinicians prescribing zoledronic acid should confirm that their laboratory uses the 2021 race-free CKD-EPI equation. If the race-adjusted equation is still in use, a Black patient with a reported eGFR of 40 mL/min/1.73m² might have a true eGFR of 34 mL/min/1.73m², placing them below the labeled cutoff.

CKD Prevalence

Black Americans have a 3.5-fold higher prevalence of end-stage kidney disease compared to White Americans 16. Early CKD (stages 2-3a) is also more common, which means a larger proportion of Black patients with osteoporosis will fall near the eGFR threshold where zoledronic acid prescribing requires extra caution. In these patients, denosumab (which has no renal elimination) is often the preferred alternative.

Screening and Treatment Disparities

The efficacy gap for zoledronic acid in Black patients is not purely pharmacologic. Much of it is an access and implementation gap.

Who Gets Treated

A 2019 study in the Journal of Bone and Mineral Research found that among Medicare beneficiaries with a documented hip fracture, only 11.9% of Black women received any osteoporosis medication within 12 months, compared to 19.3% of White women 17. Both numbers are low. The racial disparity on top of the overall treatment gap means Black patients are doubly disadvantaged.

The Clinical Assumption Problem

Dr. Andrea Singer, chief medical officer of the Bone Health & Osteoporosis Foundation, has stated: "The misconception that African American women do not develop osteoporosis remains one of the most persistent and harmful myths in bone health. It leads directly to missed diagnoses and delayed treatment" 9.

This assumption manifests in measurable ways. A 2022 analysis of electronic health records across 14 U.S. Health systems showed that Black women aged 65+ had 42% fewer DXA orders and 38% fewer bisphosphonate prescriptions per capita compared to White women, even after adjusting for BMI, fracture history, and comorbidities 7.

Practical Recommendations for Clinicians

The limited race-specific data does not mean zoledronic acid should be withheld from Black patients. It means clinicians should apply the drug thoughtfully, accounting for the population-level factors outlined above.

Pre-Infusion Checklist for Black Patients

1. Check 25(OH)D level. Replete to ≥20 ng/mL (and preferably ≥30 ng/mL) before infusion. Use cholecalciferol 50,000 IU weekly for 8 weeks if levels are below 20 ng/mL.
2. Verify the eGFR equation. Confirm your lab uses the 2021 CKD-EPI creatinine equation without a race coefficient. If eGFR is 35-45 mL/min/1.73m², consider cystatin C confirmation.
3. Do not skip DXA. Higher population-average BMD does not predict individual fracture risk. Screen per USPSTF guidelines: all women ≥65, and younger postmenopausal women with risk factors 18.
4. Use FRAX as a floor, not a ceiling. If a Black patient has clinical risk factors (glucocorticoids, parental hip fracture, secondary osteoporosis), do not defer treatment solely because the FRAX score is borderline.
5. Ensure calcium intake. Total daily calcium of 1,000-1,200 mg from diet plus supplements. Black adults have lower average dairy intake, so supplementation is often needed.

Post-Infusion Monitoring

Monitor serum calcium at 10-14 days post-infusion in patients who were vitamin D insufficient. Schedule the next infusion at 12 months. Reassess BMD at 3 years to determine whether a bisphosphonate holiday is appropriate, applying the same criteria used in the HORIZON extension trial (T-score at hip better than -2.5 and no interval fractures) 19.

The annual infusion schedule makes zoledronic acid a strong option when oral bisphosphonate adherence is a concern. Across all racial groups, oral bisphosphonate persistence at 12 months is below 50% 20. A single yearly IV infusion removes the daily or weekly dosing burden entirely.